1. Home
  2. FSM vs TLX Comparison

FSM vs TLX Comparison

Compare FSM & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FSM

Fortuna Silver Mines Inc (Canada)

HOLD

Current Price

$10.41

Market Cap

2.9B

ML Signal

HOLD

Logo Telix Pharmaceuticals Limited American Depositary Shares

TLX

Telix Pharmaceuticals Limited American Depositary Shares

HOLD

Current Price

$7.42

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSM
TLX
Founded
1990
2015
Country
Canada
Australia
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FSM
TLX
Price
$10.41
$7.42
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$11.00
$21.00
AVG Volume (30 Days)
7.0M
198.6K
Earning Date
11-05-2025
01-15-2026
Dividend Yield
N/A
N/A
EPS Growth
809.52
N/A
EPS
0.74
0.04
Revenue
$1,256,829,000.00
$664,225,558.00
Revenue This Year
$0.28
N/A
Revenue Next Year
$11.27
N/A
P/E Ratio
$13.46
$177.77
Revenue Growth
68.17
55.35
52 Week Low
$4.13
$7.49
52 Week High
$10.38
$30.36

Technical Indicators

Market Signals
Indicator
FSM
TLX
Relative Strength Index (RSI) 62.55 29.34
Support Level $9.22 $7.49
Resistance Level $10.27 $8.22
Average True Range (ATR) 0.43 0.18
MACD -0.02 -0.03
Stochastic Oscillator 97.58 6.36

Price Performance

Historical Comparison
FSM
TLX

About FSM Fortuna Silver Mines Inc (Canada)

Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'Ivoire, Mexico, and Peru. The company's segment consists of Mansfield, Sanu, Sango, Cuzcatlan, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d'Ivoire location.

About TLX Telix Pharmaceuticals Limited American Depositary Shares

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Share on Social Networks: